Skip to main content
SpringerLink
Log in

Attention and Intervention of Oncologists on Oxaliplatin-induced Adverse Reactions in Mainland China: A Cross-sectional Internet-based Survey

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

This cross-sectional study aimed to investigate the current attention and intervention of oncologists on oxaliplatin (OXA)-induced adverse reactions (ADRs).

Methods

In 31 provinces or administrative regions across China, 401 oncologists were surveyed through a self-designed questionnaire. The survey queried the basic information of respondents, clinical use of OXA, OXA-induced ADRs, and relative interventions. Chi-square tests and multiple logistic regression were used to explore the sociodemographic factors influencing the safety perception of OXA and the relevant interventions.

Results

The survey showed that the age of respondents was mainly distributed between 30 and 40 years and the working period for most oncologists was no more than 5 years. Oncologists with long working years were more willing to conduct patient education and inquire about ADRs than those with short working years. The rate of ADRs reported by oncologists with intermediate professional titles was significantly higher than that reported by oncologists with junior and senior professional titles.

Conclusion

Our findings indicate that oncologists in mainland China are concerned about OXA-induced ADRs, but the reporting of ADRs still needs to be strengthened. Therefore, training and educational programs are urgently needed to improve the risk management of OXA-induced ADRs among oncologists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 2000, 18: 2938–2947

    Article  Google Scholar 

  2. Vyskocil J, Tucek S, Kiss I, et al. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening. Int Immunopharmacol, 2019, 74: 105728

    Article  Google Scholar 

  3. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother, 2004, 5(10): 2159–2170

    Article  Google Scholar 

  4. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009, 27: 3109–3116

    Article  Google Scholar 

  5. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw, 2020, 18(7): 806–815

    Article  Google Scholar 

  6. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021, 19(3): 329–359

    Article  Google Scholar 

  7. Mathé G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother, 1986, 40: 372–376

    Google Scholar 

  8. Extra J M, Espie M, F Calvo, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol, 2002, 25: 299–303

    Article  Google Scholar 

  9. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol, 2002, 29(5 Suppl 15): 11–20

    Article  Google Scholar 

  10. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res, 2000, 6(4): 1205–1218

    Google Scholar 

  11. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs, 2011, 15: 182–188

    Article  Google Scholar 

  12. Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 2003,97:2301–2307

    Article  Google Scholar 

  13. Stefansson M, Nygren P. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol, 2016, 55: 1227–1235

    Article  Google Scholar 

  14. Drott J, Fomichov V, Starkhammar H, et al. Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities: A Longitudinal Study Among Patients With Colorectal Cancer. Cancer Nurs, 2019, 42: E40–E48

    Article  Google Scholar 

  15. Aroldi F, Prochilo T, Bertocchi P, et al. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother, 2015, 27: 63–66

    Article  Google Scholar 

  16. van Mierlo KM, Zhao J, Kleijnen J, et al. The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis. Surg Oncol, 2016, 25: 298–307

    Article  Google Scholar 

  17. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg, 2008, 247: 118–124

    Article  Google Scholar 

  18. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol, 2006, 24: 2065–2072

    Article  Google Scholar 

  19. Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother, 1989, 43: 237–250

    Article  Google Scholar 

  20. Dieras V, Bougnoux P, Petit T, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/− taxane-pretreated ovarian cancer patients. Ann Oncol, 2002, 13: 258–266

    Article  Google Scholar 

  21. Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer, 1998, 34: 1124–1127

    Article  Google Scholar 

  22. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol, 2002, 20: 1767–1774

    Article  Google Scholar 

  23. Yu Z, Huang R, Zhao L, et al. Safety Profile of Oxaliplatin in 3687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Front Oncol, 2021, 11: 757196

    Article  Google Scholar 

  24. Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (LOHP): global safety in 682 patients. Proc Am Soc Clin Oncol, 1995, 14: 209 (abstract 513)

    Google Scholar 

  25. Hewitt MR, Sun W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer, 2006, 6: 114–117

    Article  Google Scholar 

  26. Sohn KH, Kang DY, Kim JY, et al. Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study. J Allergy Clin Immunol Pract, 2018, 6(5): 1642–1648.e2

    Article  Google Scholar 

  27. Li M, Jiang C, Yang JW, et al. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A retrospective Multicenter Analysis. Curr Med Sci, 2021, 41(4): 827–831

    Article  Google Scholar 

  28. Hoff PM, Saad ED, Costa F, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer, 2012, 11: 93–100

    Article  Google Scholar 

  29. Lenz G, Hacker UT, Kern W, et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs, 2003, 14(9): 731–733

    Article  Google Scholar 

  30. Herrstedt J. The latest consensus on antiemetics. Curr Opin Oncol, 2018, 30(4): 233–239

    Article  Google Scholar 

  31. Kang L, Tian Y, Xu S, et al. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol, 2021, 268(9): 3269–3282

    Article  Google Scholar 

  32. Hewitt MR, Sun W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer, 2006, 6(2): 114–117

    Article  Google Scholar 

  33. Shroukh WA, Shakhatreh FM, Yasein NA, et al. A survey on the knowledge, attitudes and practices of physicians towards pharmacovigilance in Jordanian health centres. Int Health, 2018, 10: 363–370

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Both authors contributed equally to this study.

Authors and Affiliations

  1. Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Wei Li, Zao-qin Yu, Min Li, Xi-min Wang, Dong Liu & Cheng-liang Zhang

  2. Rehabilitation Division, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Lu Xiao

Authors
  1. Wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zao-qin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Min Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xi-min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cheng-liang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Dong Liu or Cheng-liang Zhang.

Ethics declarations

The authors declare no conflicts of interest.

Author Cheng-liang ZHANG is a member of the Young Editorial Board for Current Medical Science. The paper was handled by other editors and has undergone rigorous peer review process. Author Cheng-liang ZHANG was not involved in the journal’s review of, or decision related to, this manuscript.

Additional information

This work was supported by the Clinical Toxicology Foundation of the Chinese Society of Toxicology (No. CST2020CT107) and the Research Project of the Drug Clinical Evaluation Professional Committee of the China Pharmaceutical Association (No. CPA-Z06-ZC-2021-004).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W., Xiao, L., Yu, Zq. et al. Attention and Intervention of Oncologists on Oxaliplatin-induced Adverse Reactions in Mainland China: A Cross-sectional Internet-based Survey. CURR MED SCI 42, 1319–1324 (2022). https://doi.org/10.1007/s11596-022-2634-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-022-2634-0

Key words

Search

Navigation